{"id":2626,"date":"2025-05-28T06:35:48","date_gmt":"2025-05-28T06:35:48","guid":{"rendered":"https:\/\/www.aesomed.com\/about\/"},"modified":"2026-03-19T14:31:09","modified_gmt":"2026-03-19T14:31:09","slug":"about","status":"publish","type":"page","link":"https:\/\/www.aesomed.com\/en\/about\/","title":{"rendered":"About"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

About<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Brand story<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In 2019, during developing novel anti-cancer
therapies, Dr. Chen’s lab, a team of Chinese-
American biologists in the U.S., serendipitously
discovered the breakthrough process for
standardized production of recombinant
exosomes.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

In 2019, during developing novel anti-cancer
therapies, Dr. Chen’s lab, a team of Chinese-
American biologists in the U.S., serendipitously
discovered the breakthrough process for
standardized production of recombinant
exosomes.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This led to the founding of AESOMED, shifting
focus to anti-aging science. After over a thousand
formulations, the optimal balance between active
ingredients and skin cells was achieved on the
313th trial. Combining patented recombinant
exosomes with our 313rd formulation, we created
signature anti-aging produc\u2014FORMULA 313.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

More than a breakthrough in science, this
laboratory-derived serial number, unveils a new
chapter in regenerative aesthetics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

More than a breakthrough in science, this
laboratory-derived serial number, unveils a new
chapter in regenerative aesthetics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

THE NEXT CHAPTER OF
REGENERATION.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Team<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\r\n \r\n \r\n
\r\n
\r\n
\r\n

Ming LI<\/h3>\r\n

CEO\uff0cCo-Founder<\/p>\r\n <\/div>\r\n

\r\n \"\u674e\u660e\u7167\u7247\"\r\n <\/div>\r\n
\r\n -<\/span>\r\n +<\/span>\r\n <\/div>\r\n <\/div>\r\n
\r\n
    \r\n
  • Over 12 years of experience in healthcare investment and management<\/li>\r\n
  • Founder of the healthcare investment firm, Kuanping Capital<\/li>\r\n
  • Former core member of the healthcare teams at Hillhouse Capital and \r\nFountainVest Partners<\/li>\r\n
  • Dual Bachelor\u2019s degrees in Mathematics and Economics, Peking University<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n \r\n \r\n
    \r\n
    \r\n
    \r\n

    Dr. Yiyou CHEN<\/h3>\r\n

    Science Co-Founder<\/p>\r\n <\/div>\r\n

    \r\n \"\u9648\u4e00\u53cb\u7167\u7247\"\r\n <\/div>\r\n
    \r\n -<\/span>\r\n +<\/span>\r\n <\/div>\r\n <\/div>\r\n
    \r\n
      \r\n
    • Serial biotech entrepreneur<\/li>\r\n
    • Successfully founded companies including New Horizon Health, CrownBio, \r\nand ImmuneOnco<\/li>\r\n
    • B.S. in Biochemistry, Peking University;Ph.D. in Experimental Pathology, University of Utah<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n \r\n \r\n
      \r\n
      \r\n
      \r\n

      Sherry SHAO<\/h3>\r\n

      COO \uff0c Co-Founder<\/p>\r\n <\/div>\r\n

      \r\n \"\u90b5\u97f5\u7af9\u7167\u7247\"\r\n <\/div>\r\n
      \r\n -<\/span>\r\n +<\/span>\r\n <\/div>\r\n <\/div>\r\n
      \r\n
        \r\n
      • Over 10 years of investment experience in consumer and technology sectors<\/li>\r\n
      • Former Investment Director at FountainVest Partners, CMC Capital, and \r\nAlibaba Strategic Investments<\/li>\r\n
      • B.A. in Economics, Renmin University; M.S. in Business, University of Illinois \r\nat Urbana-Champaign<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n \r\n \r\n
        \r\n
        \r\n
        \r\n

        Dr. Zhixiang WU<\/h3>\r\n

        R&D Director<\/p>\r\n <\/div>\r\n

        \r\n \"\u5434\u5fd7\u7965\u7167\u7247\"\r\n <\/div>\r\n
        \r\n -<\/span>\r\n +<\/span>\r\n <\/div>\r\n <\/div>\r\n
        \r\n
          \r\n
        • Extensive experience in biotechR&D and clinical research<\/li>\r\n
        • Ph.D. in Biology, Shanghai Jiao Tong University<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n<\/div>\r\n\r\n